BNP Paribas Financial Markets
BDTX icon

BNP Paribas Financial Markets’s Black Diamond Therapeutics BDTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8K Buy
8,027
+6,315
+369% +$15.4K ﹤0.01% 5322
2026
Q1 		$3.65K Sell
1,712
-919
-35% -$2.19K ﹤0.01% 5355
2025
Q4 		$6.39K Buy
2,631
+2,467
+1,504% +$8.74K ﹤0.01% 5227
2025
Q3 		$622 Sell
164
-595
-78% -$1.74K ﹤0.01% 5291
2025
Q2 		$1.88K Sell
759
-1,371
-64% -$2.64K ﹤0.01% 5066
2025
Q1 		$3.3K Sell
2,130
-1,983
-48% -$4.16K ﹤0.01% 4920
2024
Q4 		$8.8K Buy
+4,113
New +$11.8K ﹤0.01% 4863

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

BNP Paribas Financial Markets's BDTX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Black Diamond Therapeutics (BDTX) stake by 369% in Q2 2026, buying an estimated $15.4K and bringing the position to 8,027 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5322.

BNP Paribas Financial Markets first reported a position in BDTX in Q4 2024 and has held it in 7 quarters since. 77 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • BNP Paribas Financial Markets held 8,027 shares of Black Diamond Therapeutics worth $14.8K as of Q2 2026.
  • BNP Paribas Financial Markets bought 6,315 Black Diamond Therapeutics shares in Q2 2026, an estimated $15.4K.
  • Black Diamond Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5322 holding.
  • BNP Paribas Financial Markets first reported a position in Black Diamond Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 77 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.